OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Garvin on the Benefits of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

August 9th 2021

Kelly Garvin, MA, BSN, RN, discusses the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.

Washington on Efforts to Address Disparities in Cancer Care

August 9th 2021

Chasity Washington, MPH, CHES, discusses strategies for addressing disparities in cancer care.

Dr. Karim on the Rationale for the CheckMate-73L Trial With Ipilimumab/Nivolumab in NSCLC

August 6th 2021

Nagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.

Dr. Mauro on Considerations for Early Treatment Initiation in Myelofibrosis

August 5th 2021

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

Dr. Thompson on Future Research Directions in CLL

August 5th 2021

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

Dr. Malhotra on the Rationale to Evaluate Racial Disparities in Lung Cancer Survivors

August 5th 2021

Jyoti Malhotra, MD, MPH, discusses the rationale to evaluate racial disparities in lung cancer survivors.

Dr. Kumar on the Clinical Implications of the AIM Study in Mantle Cell Lymphoma

August 4th 2021

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma.

Dr. Cohen on the Standardization of Triplet Chemotherapy in CRC

August 4th 2021

Stacey A. Cohen, MD, discusses the standardization of triplet-based chemotherapy regimens in colorectal cancer.

Dr. Pegram on Considerations for Treatment Selection in HER2+ Breast Cancer

August 4th 2021

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

Dr. Flowers on Efforts to Improve Frontline Treatment in DLBCL

August 3rd 2021

Christopher Flowers, MD, discusses efforts to improve the frontline standard of care in diffuse large B-cell lymphoma.

Dr. Ozguroglu on the Individualization of Treatment in NSCLC

August 3rd 2021

Mustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.

Dr. Puri on Clinically Relevant Biomarkers in SCLC

August 3rd 2021

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer.

Dr. Manasanch on Key Takeaways From CASSIOPEIA in Multiple Myeloma

August 3rd 2021

Elisabet E. Manasanch, MD, discusses key lessons learned from the phase 3 CASSIOPEIA trial in patients with newly diagnosed multiple myeloma.

Dr. Rampal on Symptoms of Disease Progression in Myelofibrosis

August 3rd 2021

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

Dr. Kumar on Patient Considerations for Treatment in Relapsed/Refractory MCL

August 3rd 2021

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

Dr. Park on Emerging CAR T-Cell Therapies in Hematologic Malignancies

August 3rd 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

Dr. Landgren on Novel Approaches Generating Excitement in Myeloma

August 3rd 2021

C. Ola Landgren, MD, PhD, discusses novel therapeutic approaches that are generating excitement in multiple myeloma.

Dr. Sam on Managing ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 3rd 2021

Christine Sam, MD, shares strategies to manage interstitial lung disease experienced with fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Morgan on the Differences in Low- and High-Risk Multiple Myeloma

August 2nd 2021

Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

Dr. Phillips on the Future of CAR T-Cell Therapy in MCL

August 2nd 2021

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.